Liraglutide 3mg Real-World Study to Investigate Metabolic Effects in Overweight and Obese Patients

Obesity and overweight are global health crises linked to numerous metabolic complications, including type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. While Liraglutide, a GLP-1 receptor agonist, is approved for weight management, its full spectrum of beneficial metabolic effects and underlying mechanisms in a real-world setting are not completely understood. Current understanding often comes from controlled clinical trials, which may not fully capture the nuances of patient responses in routine clinical practice. This study aims to bridge that gap by collecting comprehensive data from patients receiving liraglutide as part of their standard care.

This observational study will collect real-life data from patients with obesity or overweight receiving Liraglutide 3mg daily via subcutaneous injection as part of their agreed clinical management in NHS or private clinics. Investigators will monitor changes in vital signs, anthropometric characteristics (weight, body mass index, body composition), and various biochemical parameters. Crucially, the study will also analyze metabolomics and micro-ribonucleotide acid (miRNA) molecules from blood tests, aiming for a deeper mechanistic understanding beyond standard clinical markers. Patients can withdraw from treatment and the study at any time.